MPI Research, the largest single-site preclinical contract research organization, and Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, announced that they will collaborate on preclinical and clinical testing of Edge’s lead product candidates, NimoGel, NimoVent, and EG-1964. The companies will combine their skills and expertise with the goal of initiating clinical trials of Edge’s portfolio of therapies that use novel implantable technology to deliver proven drugs directly to the site of brain injury.
Paul Oskar, MBA, Vice President and General Manager of Drug Safety and Preclinical Sciences at MPI Research notes, “We are impressed by Edge’s world-class science in brain hemorrhage and drug delivery. Together, MPI Research and Edge have the expertise and capabilities needed to accelerate the preclinical and clinical programs for Edge’s promising and potentially life-saving hospital-based therapies.”
The collaboration creates a preferred partnership relationship in which MPI Research will act as Edge’s primary service provider for pharmacologic, analytical, and safety in preclinical testing, and will also provide analytical services for clinical testing. This collaboration will allow Edge to gain multiple cost efficiencies while still retaining asset ownership and ownership of its strategic decision-making.
“Partnering with MPI Research allows Edge to access additional expertise and capabilities on a larger scale, helping to advance our lead hospital products into clinical trials,” said R. Loch Macdonald, MD, PhD, Edge Chief Scientific Officer and neurosurgeon. “We look forward to a strong collaboration focused on the shared goal of saving the lives of brain-injured patients.”
Date: April 3, 2012
Source: MPI Research https://www.mpiresearch.com/
Filed Under: Drug Discovery
